240 related articles for article (PubMed ID: 23609190)
1. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis.
Wang Z; Zhang H; Zhang P; Li J; Shan Z; Teng W
Med Oncol; 2013; 30(2):577. PubMed ID: 23609190
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
5. Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.
Peng Y; Li C; Luo DC; Ding JW; Zhang W; Pan G
Molecules; 2014 Aug; 19(8):11586-99. PubMed ID: 25100252
[TBL] [Abstract][Full Text] [Related]
6. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
7. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
8. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
[TBL] [Abstract][Full Text] [Related]
9. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
[TBL] [Abstract][Full Text] [Related]
11. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
12. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
[TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
14. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma.
Zhang J; Liu Y; Liu Z; Wang XM; Yin DT; Zheng LL; Zhang DY; Lu XB
Int J Med Sci; 2013; 10(5):585-92. PubMed ID: 23533107
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma.
Chen W; Li G; Li Z; Zhu J; Wei T; Lei J
Endocrine; 2022 Mar; 75(3):846-855. PubMed ID: 34854020
[TBL] [Abstract][Full Text] [Related]
16. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.
Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q
Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report.
Geraldo MV; Fuziwara CS; Friguglieti CU; Costa RB; Kulcsar MA; Yamashita AS; Kimura ET
Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):552-7. PubMed ID: 23295297
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma.
Liu Y; Li L; Liu Z; Yuan Q; Lu X
Cancer Biomark; 2018; 22(4):727-732. PubMed ID: 29945344
[TBL] [Abstract][Full Text] [Related]
19. MiR-137 acts as a tumor suppressor in papillary thyroid carcinoma by targeting CXCL12.
Dong S; Jin M; Li Y; Ren P; Liu J
Oncol Rep; 2016 Apr; 35(4):2151-8. PubMed ID: 26847706
[TBL] [Abstract][Full Text] [Related]
20. miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.
Wen Q; Zhao J; Bai L; Wang T; Zhang H; Ma Q
Oncol Rep; 2015 Oct; 34(4):2202-10. PubMed ID: 26239517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
